1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Neuropathy - Pipeline Review, H2 2013

Neuropathy - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 36 pages

Neuropathy - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Neuropathy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathy. Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Neuropathy.
- A review of the Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Neuropathy.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neuropathy pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Neuropathy - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neuropathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Neuropathy 7
Neuropathy Therapeutics under Development by Companies 9
Neuropathy Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Neuropathy Therapeutics - Products under Development by Companies 13
Neuropathy Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Neuropathy Therapeutics Development 15
AstraZeneca PLC 15
MAKScientific, LLC 16
TheraQuest Biosciences, LLC 17
Beech Tree Labs, Inc. 18
Neuropathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
minocycline - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
mepivacaine hydrochloride - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
AR-C-102222 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
AM-1710 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
A-836339 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Neuropathy Therapeutics - Dormant Products 31
Neuropathy - Product Development Milestones 32
Featured News and Press Releases 32
Jun 25, 2012: Baxter Announces FDA Approval For Gammagard Liquid As Treatment For Multifocal Motor Neuropathy 32
May 04, 2012: Pfizer Stops Phase III Trial Of Lyrica Capsules CV In Neuropathic Pain Associated With HIV Neuropathy 33
Apr 27, 2012: Baxter Presents Efficacy And Safety Data Evaluating Gammagard Liquid For Multifocal Motor Neuropathy At AAN Annual Meeting 33
Apr 13, 2011: Santhera To Present Catena Clinical Study Results At 2011 American Academy Of Neurology Annual Meeting 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 36
Disclaimer 36



List of Tables

Number of Products Under Development for Neuropathy, H2 2013 7
Products under Development for Neuropathy - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
AstraZeneca PLC, H2 2013 15
MAKScientific, LLC, H2 2013 16
TheraQuest Biosciences, LLC, H2 2013 17
Beech Tree Labs, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 23
Neuropathy Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Neuropathy, H2 2013 7
Products under Development for Neuropathy - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Assessment by Route of Administration, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Molecule Type, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 23



Companies Mentioned

AstraZeneca PLC
MAKScientific, LLC
TheraQuest Biosciences, LLC
Beech Tree Labs, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - ...

Trigeminal Neuralgia - Pipeline Review, H2 2016

Trigeminal Neuralgia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Trigeminal Neuralgia - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape. ...

Optic Neuropathy - Pipeline Review, H2 2016

Optic Neuropathy - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Optic Neuropathy - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Optic Neuropathy - Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.